27.11.2012 Views

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />

PRODUCTS IN DEVELOPMENT: Name Status<br />

Active ingredients:<br />

Mandipropamid in late development<br />

Insecticide in late development<br />

Fungicides in early development<br />

Herbicide 1 in early development<br />

Herbicide 2 in early development<br />

Corn traits:<br />

Corn Root Worm (CRW) in elite breeding, planned<br />

launch in 2007<br />

GT / CRW in elite breeding, planned<br />

launch in 2007<br />

CRW / ECB in elite breeding, planned<br />

launch in 2008<br />

GT / CRW / ECB in elite breeding, planned<br />

launch in 2008<br />

Corn amylase (biofuels) in late development<br />

Corn phytase in early development<br />

Synthetech Inc.<br />

1290 Industrial Way<br />

Albany OR 97322, US<br />

Phone: (541) 967-6575; Fax: (541) 967-9424<br />

Web: www.synthetech.com<br />

E-mail: customer@synthetech.com<br />

KEY PERSONNEL: Daniel T. Fagan; Chairman<br />

Dr. Gregory Hahn; President and COO<br />

Gary Weber; CFO and VP, Finance and Administration<br />

Dr. Mike Standen; Director, Technology<br />

Brett Reynolds; Director, Sales and Marketing<br />

EMPLOYEES: 62 employees<br />

HISTORY: Founded in 1981 by Paul Ahrens<br />

Acquired fine chemicals manufacturing facilities in Albany, Ore. (1987)<br />

Acquired technology assets and customer lists of Colorado Biotechnology<br />

Associates Inc. (1/06)<br />

FACILITIES: 25,000 sq. ft. manufacturing plant, research labs, warehouse and<br />

administrative offices<br />

20,000 sq. ft. pilot manufacturing plant<br />

STOCK-FINANCIAL HISTORY: NASDAQ--NZYM<br />

IPO--3M shares at $1/share, $3M (1984)<br />

Revenue $5.819M (YE 06) compared to $9.751M (YE 05)<br />

Net loss (YE 06) compared to (YE 05)<br />

Loss per share (YE 06) compared to (YE 05)<br />

PRIVATE PLACEMENTS: $1M private placement of stock and warrants (8/91)<br />

$1M exercise of above warrants (3/96)<br />

BUSINESS STRATEGY: Develop and market amino acid derivatives<br />

Develop and scale-up bio-organic processes for chiral fine chemicals and<br />

pharmaceutical intermediates, especially specialty amino acids and<br />

derivatives<br />

AGREEMENTS: Name Products Content of Agreement Date<br />

Biomeasure Inc. specialty amino acids supply and<br />

technology<br />

agreement<br />

5/89<br />

Miwon Korea aspartame licensing agreement 12/89<br />

Copyright ©2006 AHC Media ® 364

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!